These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Upadhyay R; Boiarsky JA; Pantsulaia G; Svensson-Arvelund J; Lin MJ; Wroblewska A; Bhalla S; Scholler N; Bot A; Rossi JM; Sadek N; Parekh S; Lagana A; Baccarini A; Merad M; Brown BD; Brody JD Cancer Discov; 2021 Mar; 11(3):599-613. PubMed ID: 33334730 [TBL] [Abstract][Full Text] [Related]
123. Author Correction: The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Schnell A; Bod L; Madi A; Kuchroo VK Cell Res; 2020 Apr; 30(4):366. PubMed ID: 32086475 [TBL] [Abstract][Full Text] [Related]
124. Death Receptors and Their Ligands in Inflammatory Disease and Cancer. Annibaldi A; Walczak H Cold Spring Harb Perspect Biol; 2020 Sep; 12(9):. PubMed ID: 31988141 [TBL] [Abstract][Full Text] [Related]
125. Top 10 Challenges in Cancer Immunotherapy. Hegde PS; Chen DS Immunity; 2020 Jan; 52(1):17-35. PubMed ID: 31940268 [TBL] [Abstract][Full Text] [Related]
126. Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling. Pan L; Fu TM; Zhao W; Zhao L; Chen W; Qiu C; Liu W; Liu Z; Piai A; Fu Q; Chen S; Wu H; Chou JJ Cell; 2019 Mar; 176(6):1477-1489.e14. PubMed ID: 30827683 [TBL] [Abstract][Full Text] [Related]
127. Perturbing the Dynamics and Organization of Cell Membrane Components: A New Paradigm for Cancer-Targeted Therapies. Bernardes N; Fialho AM Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30518103 [TBL] [Abstract][Full Text] [Related]
128. A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Shivange G; Urbanek K; Przanowski P; Perry JSA; Jones J; Haggart R; Kostka C; Patki T; Stelow E; Petrova Y; Llaneza D; Mayo M; Ravichandran KS; Landen CN; Bhatnagar S; Tushir-Singh J Cancer Cell; 2018 Aug; 34(2):331-345.e11. PubMed ID: 30107179 [TBL] [Abstract][Full Text] [Related]
129. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246 [TBL] [Abstract][Full Text] [Related]
130. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Yeku OO; Purdon TJ; Koneru M; Spriggs D; Brentjens RJ Sci Rep; 2017 Sep; 7(1):10541. PubMed ID: 28874817 [TBL] [Abstract][Full Text] [Related]
131. Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Yamada A; Arakaki R; Saito M; Kudo Y; Ishimaru N Front Immunol; 2017; 8():403. PubMed ID: 28424702 [TBL] [Abstract][Full Text] [Related]
132. Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3. Liu W; Ramagopal U; Cheng H; Bonanno JB; Toro R; Bhosle R; Zhan C; Almo SC Structure; 2016 Nov; 24(11):2016-2023. PubMed ID: 27806260 [TBL] [Abstract][Full Text] [Related]
133. Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes. Chen B; Le W; Wang Y; Li Z; Wang D; Ren L; Lin L; Cui S; Hu JJ; Hu Y; Yang P; Ewing RC; Shi D; Cui Z Theranostics; 2016; 6(11):1887-98. PubMed ID: 27570558 [TBL] [Abstract][Full Text] [Related]
134. TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2. Tamada T; Shinmi D; Ikeda M; Yonezawa Y; Kataoka S; Kuroki R; Mori E; Motoki K Sci Rep; 2015 Dec; 5():17936. PubMed ID: 26672965 [TBL] [Abstract][Full Text] [Related]
135. The role of CD95 and CD95 ligand in cancer. Peter ME; Hadji A; Murmann AE; Brockway S; Putzbach W; Pattanayak A; Ceppi P Cell Death Differ; 2015 Apr; 22(4):549-59. PubMed ID: 25656654 [TBL] [Abstract][Full Text] [Related]
136. CD95 and CD95L promote and protect cancer stem cells. Ceppi P; Hadji A; Kohlhapp FJ; Pattanayak A; Hau A; Liu X; Liu H; Murmann AE; Peter ME Nat Commun; 2014 Nov; 5():5238. PubMed ID: 25366259 [TBL] [Abstract][Full Text] [Related]
137. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Graves JD; Kordich JJ; Huang TH; Piasecki J; Bush TL; Sullivan T; Foltz IN; Chang W; Douangpanya H; Dang T; O'Neill JW; Mallari R; Zhao X; Branstetter DG; Rossi JM; Long AM; Huang X; Holland PM Cancer Cell; 2014 Aug; 26(2):177-89. PubMed ID: 25043603 [TBL] [Abstract][Full Text] [Related]
138. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Melero I; Rouzaut A; Motz GT; Coukos G Cancer Discov; 2014 May; 4(5):522-6. PubMed ID: 24795012 [TBL] [Abstract][Full Text] [Related]